GHRH + GHRP Blend

CJC-1295 / Ipamorelin Blend

A pre-combined synergistic stack pairing a GHRH analog (Mod GRF 1–29) with a selective ghrelin-mimetic for amplified, clean growth hormone elevation in a single injection.

◆ Evidence Level: Limited Human DataThis combination pairs a GHRH analog with a growth hormone secretagogue. Each component has limited human data individually. No studies exist on the specific combination. Not FDA-approved. See references →

What Is the CJC-1295 / Ipamorelin Blend?

The CJC-1295/Ipamorelin blend is a pre-combined peptide that pairs two complementary growth hormone–releasing agents in a single vial. CJC-1295 (No DAC), also known as Mod GRF 1–29, is a GHRH analog that primes the pituitary to release GH. Ipamorelin is a selective ghrelin-mimetic (GHRP) that triggers the actual GH pulse.

Together they produce a synergistic effect: the GH output of the combination is significantly greater than either peptide used alone. This blend simplifies dosing by eliminating the need to reconstitute and draw from two separate vials.

Mechanism of Action

The two peptides work through different but complementary pathways:

CJC-1295 (GHRH analog): Binds GHRH receptors on pituitary somatotrophs, amplifying the magnitude and duration of each GH pulse
Ipamorelin (GHRP): Activates ghrelin receptors (GHS-R1a), initiating a GH secretion pulse independent of GHRH timing
Synergistic effect: GHRH amplification + GHRP initiation produces 2–3x greater GH output than either alone
Clean profile: Ipamorelin’s selectivity means no significant cortisol, prolactin, or appetite elevation
Preserved pulsatility: Both peptides work with the body’s natural feedback loops rather than overriding them

Research Applications

Maximized GH output via dual-pathway stimulation in a single injection
Body recomposition research (simultaneous fat loss and lean mass preservation)
Deep sleep enhancement and recovery optimization
Anti-aging protocols targeting skin, hair, and connective tissue quality
Post-training recovery acceleration with minimal side-effect burden
Simplified GH secretagogue dosing without multi-vial reconstitution

Dosing Protocol

The blend is administered via subcutaneous injection on an empty stomach. Each dose delivers both peptides simultaneously:

Protocol	Dose	Frequency	Notes
Standard	100 mcg each	2–3x daily	Fasted; morning, pre-workout, bedtime
Sleep-focused	100 mcg each	Once nightly	30 min before bed, empty stomach
Aggressive	200 mcg each	2–3x daily	Advanced; higher GH amplitude

Inject subcutaneously on an empty stomach. Avoid food for 20–30 minutes post-injection. The pre-bed dose is the most impactful window. Typical research cycles run 8–16 weeks.

Preparation & Storage

Reconstitution

Supplies: peptide vial, bacteriostatic water, insulin syringes (29–31 gauge), alcohol swabs.

Clean both vial tops with alcohol swabs and let dry
Draw 2 mL of bacteriostatic water into the syringe
Insert needle into peptide vial at an angle against the glass wall
Let water run slowly down the side – never squirt directly onto powder
Gently swirl until fully dissolved – never shake
Solution should be clear – discard if cloudy or contains particles

Storage

Unreconstituted: Room temp or refrigerated, stable up to 24 months
Reconstituted: Refrigerate at 2–8°C (36–46°F), use within 4–6 weeks
Protect from direct sunlight and heat
Do not freeze reconstituted solution

Cycling

Typical research cycle: 8–12 weeks. Results generally reported within 1–2 weeks.